<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055939</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000271888</org_study_id>
    <secondary_id>DAIICHI-8951A-PRT033</secondary_id>
    <secondary_id>SJCRH-DXRMS</secondary_id>
    <nct_id>NCT00055939</nct_id>
  </id_info>
  <brief_title>Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma</brief_title>
  <official_title>A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating children&#xD;
      who have relapsed or refractory rhabdomyosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response rate (complete and partial responses) in pediatric&#xD;
           patients with relapsed or refractory rhabdomyosarcoma treated with exatecan mesylate.&#xD;
&#xD;
        -  Determine the time to tumor progression in patients treated with this drug.&#xD;
&#xD;
        -  Determine the median survival and survival at 6 and 12 months in patients treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Assess pain in patients treated with this drug.&#xD;
&#xD;
        -  Evaluate the quantitative and qualitative toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Evaluate the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, multicenter study.&#xD;
&#xD;
      Patients receive exatecan mesylate IV over 30 minutes on days 1-5. Treatment repeats every 3&#xD;
      weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients who achieve a complete response (CR) receive 6 additional courses beyond CR.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 13-27 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exatecan mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent or resistant rhabdomyosarcoma&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  The following are not considered measurable disease:&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural effusion&#xD;
&#xD;
                    -  Lytic bone lesions&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 (over 10 years old)&#xD;
&#xD;
          -  Lansky 60-100% (10 years old and under)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 750/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.5 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Albumin at least 2.8 g/dL&#xD;
&#xD;
          -  AST or ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver&#xD;
             metastases present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No life threatening illness (unrelated to tumor) within the past 6 months&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No concurrent active serious infection&#xD;
&#xD;
          -  No concurrent uncontrolled infection&#xD;
&#xD;
          -  No overt psychosis or other incompetency that would preclude study compliance or&#xD;
             giving informed consent&#xD;
&#xD;
          -  No other concurrent noncancer-related illness that would preclude study participation&#xD;
             or follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 months since prior autologous bone marrow or stem cell transplantation&#xD;
&#xD;
          -  No concurrent anticancer biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior adjuvant or systemic chemotherapy&#xD;
&#xD;
          -  Prior topoisomerase I inhibitor therapy allowed&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior extensive radiotherapy to the cranial-spinal axis, whole&#xD;
             pelvis, or 25% of marrow reserve&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No concurrent anticancer surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 28 days since prior investigational drugs (including analgesics or&#xD;
             antiemetics)&#xD;
&#xD;
          -  No more than 2 prior regimens for rhabdomyosarcoma&#xD;
&#xD;
          -  No concurrent grapefruit-containing beverages or foods&#xD;
&#xD;
          -  No other concurrent investigational drugs during and for 28 days after final dose of&#xD;
             study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L. DeJager, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhabdomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exatecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

